

U.S. General Anesthesia Drugs Market Size, Share & Trends Analysis Report By Drug (Propofol, Sevoflurane), By Route Of Administration (Intravenous, Inhaled), By End-use (Hospitals, Ambulatory Surgical Centers), By Application, By Country, And Segment Forecasts, 2025 - 2030

<https://marketpublishers.com/r/UD5167A6A6A3EN.html>

Date: January 2025

Pages: 70

Price: US\$ 5,950.00 (Single User License)

ID: UD5167A6A6A3EN

Abstracts

This report can be delivered to the clients within 3 Business Days

U.S. General Anesthesia Drugs Market Growth & Trends

The U.S. general anesthesia drugs market size is projected to reach USD 2.03 billion by 2030, and is anticipated to grow at a CAGR of 2.82% from 2025 to 2030, according to Grand View Research, Inc. The rising number of surgical procedures primarily drives this growth. The American Society of Anesthesiologists (ASA) highlights a consistent increase in surgeries, attributed to an aging population, the growing prevalence of chronic diseases, and advancements in surgical techniques. The CDC reported in February 2024 that approximately 129 million Americans have at least one major chronic disease, such as cancer, heart disease, diabetes, and hypertension. This high prevalence of chronic conditions necessitates numerous cardiovascular and other surgeries, which in turn drives the demand for effective general anesthesia drugs.

Advancements in anesthesia technology are another critical driver. Innovations such as ultra-short-acting anesthetics, like remifentanyl, offer improved control over anesthesia depth and faster recovery times, enhancing patient outcomes and driving market growth. Additionally, the development of advanced delivery systems and monitoring technologies, including automated anesthesia delivery systems, has revolutionized

anesthesia practices by improving precision and safety.

Regulatory developments also play a significant role. The FDA's expedited approval pathways for breakthrough therapies facilitate quicker access to new and effective anesthetics. For instance, the recent approval of ZYNRELEFTM, a novel extended-release anesthetic, illustrates how regulatory advancements support the introduction of innovative products.

U.S. General Anesthesia Drugs Market Report Highlights

Based on drug, the propofol segment dominated the market with a substantial revenue share of 25.52% in 2024 and is also expected to grow at the fastest CAGR during the forecast period, driven by its widespread use as a preferred agent for induction and maintenance of general anesthesia.

Based on route of administration, the intravenous segment held the largest revenue share in 2024 and is also expected to grow at the fastest CAGR of 3.03% during the forecast period.

Based on application, the knee and hip replacements segment dominated the market, capturing a substantial revenue share.

Based on end-use, the hospitals segment dominated the market, capturing a substantial revenue share of 67.05% in 2024. Hospitals are the primary settings for major surgeries and complex medical procedures that require general anesthesia.

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
 - 1.2.1. Drug
 - 1.2.2. Route of Administration
 - 1.2.3. End Use
 - 1.2.4. Application
 - 1.2.5. Regional scope
 - 1.2.6. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
 - 1.4.1. Purchased database
 - 1.4.2. GVR's internal database
 - 1.4.3. Secondary sources
 - 1.4.4. Primary research
 - 1.4.5. Details of primary research
 - 1.4.5.1. Data for primary interviews in North America
- 1.5. Information or Data Analysis
 - 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
 - 1.7.1. Commodity flow analysis (Model 1)
 - 1.7.2. Approach 1: Commodity flow approach
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Outlook
- 2.2. Segment Outlook
 - 2.2.1. Drug Outlook
 - 2.2.2. Route of Administration
 - 2.2.3. End Use
 - 2.2.4. Application
 - 2.2.5. Regional outlook

2.3. Competitive Insights

CHAPTER 3. U.S. GENERAL ANESTHESIA DRUGS MARKET VARIABLES, TRENDS & SCOPE

3.1. Market Lineage Outlook

- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook

3.2. Market Dynamics

- 3.2.1. Market driver analysis
 - 3.2.1.1. Increasing Volume Of Surgical Procedures
 - 3.2.1.2. Advancements In Anesthesia Technology
 - 3.2.1.3. Regulatory Developments
- 3.2.2. Market restraint analysis
 - 3.2.2.1. Regulatory and Compliance Challenges
 - 3.2.2.2. Adverse Effects and Safety Concerns

3.3. U.S. General Anesthesia Drugs Market Analysis Tools

- 3.3.1. Industry Analysis - Porter's
 - 3.3.1.1. Supplier power
 - 3.3.1.2. Buyer power
 - 3.3.1.3. Substitution threat
 - 3.3.1.4. Threat of new entrant
 - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
 - 3.3.2.1. Political landscape
 - 3.3.2.2. Technological landscape
 - 3.3.2.3. Economic landscape

CHAPTER 4. U.S. GENERAL ANESTHESIA DRUGS MARKET: DRUG ESTIMATES & TREND ANALYSIS

4.1. U.S. General Anesthesia Drugs Market: Drug Dashboard

4.2. U.S. General Anesthesia Drugs Market: Drug Movement Analysis

4.3. U.S. General Anesthesia Drugs Market by Drug, Revenue

4.4. Sevoflurane

- 4.4.1. Sevoflurane market estimates and forecasts 2018 to 2030 (USD Million)

4.5. Propofol

- 4.5.1. Propofol market estimates and forecasts 2018 to 2030 (USD Million)

4.6. Dexmedetomidine

- 4.6.1. Dexmedetomidine market estimates and forecasts 2018 to 2030 (USD Million)
- 4.7. Remifentanil
 - 4.7.1. Remifentanil market estimates and forecasts 2018 to 2030 (USD Million)
- 4.8. Desflurane
 - 4.8.1. Desflurane market estimates and forecasts 2018 to 2030 (USD Million)
- 4.9. Midazolam
 - 4.9.1. Midazolam market estimates and forecasts 2018 to 2030 (USD Million)
- 4.10. Others
 - 4.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 5. U.S. GENERAL ANESTHESIA DRUGS MARKET: ROUTE OF ADMINISTRATION ESTIMATES & TREND ANALYSIS

- 5.1. U.S. General Anesthesia Drugs Market: Route of Administration Dashboard
- 5.2. U.S. General Anesthesia Drugs Market: Route of Administration Movement Analysis
- 5.3. U.S. General Anesthesia Drugs Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
- 5.4. Intravenous
 - 5.4.1. Intravenous market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5. Inhaled
 - 5.5.1. Inhaled market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 6. U.S. GENERAL ANESTHESIA DRUGS MARKET: END USE ESTIMATES & TREND ANALYSIS

- 6.1. U.S. General Anesthesia Drugs Market: End Use Dashboard
- 6.2. U.S. General Anesthesia Drugs Market: End Use Movement Analysis
- 6.3. U.S. General Anesthesia Drugs Market Estimates and Forecasts, By End Use, Revenue (USD Million)
- 6.4. Hospitals
 - 6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5. Ambulatory Surgical Centers
 - 6.5.1. Ambulatory Surgical Centers market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6. Others
 - 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 7. U.S. GENERAL ANESTHESIA DRUGS MARKET: APPLICATION

ESTIMATES & TREND ANALYSIS

- 7.1. U.S. General Anesthesia Drugs Market: Application Dashboard
- 7.2. U.S. General Anesthesia Drugs Market: Application Movement Analysis
- 7.3. U.S. General Anesthesia Drugs Market Estimates and Forecasts, By Application, Revenue (USD Million)
- 7.4. Heart Surgeries
 - 7.4.1. Heart Surgeries market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5. Cancer
 - 7.5.1. Cancer market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6. General Surgery
 - 7.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7. Knee and hip replacements
 - 7.7.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
- 7.8. Other
 - 7.8.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 8. U.S. GENERAL ANESTHESIA DRUGS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY DRUG, ROUTE OF ADMINISTRATION, END USE AND APPLICATION

- 8.1. Regional Dashboard
- 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
 - 8.2.1. U.S.
 - 8.2.1.1. Key country dynamics
 - 8.2.1.2. Regulatory framework/ reimbursement structure
 - 8.2.1.3. Competitive scenario
 - 8.2.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 9. COMPETITIVE LANDSCAPE

- 9.1. Company/Competition Categorization
- 9.2. Vendor Landscape
 - 9.2.1. List of key distributors and channel partners
 - 9.2.2. Key company market share analysis, 2024
 - 9.2.3. Baxter International Inc.
 - 9.2.3.1. Company overview
 - 9.2.3.2. Financial performance
 - 9.2.3.3. Drug benchmarking

- 9.2.3.4. Strategic initiatives
- 9.2.4. AstraZeneca
 - 9.2.4.1. Company overview
 - 9.2.4.2. Financial performance
 - 9.2.4.3. Drug benchmarking
 - 9.2.4.4. Strategic initiatives
- 9.2.5. AbbVie Inc.
 - 9.2.5.1. Company overview
 - 9.2.5.2. Financial performance
 - 9.2.5.3. Drug benchmarking
 - 9.2.5.4. Strategic initiatives
- 9.2.6. B. Braun Melsungen AG
 - 9.2.6.1. Company overview
 - 9.2.6.2. Financial performance
 - 9.2.6.3. Drug benchmarking
 - 9.2.6.4. Strategic initiatives
- 9.2.7. Fresenius SE & Co. KgaA
 - 9.2.7.1. Company overview
 - 9.2.7.2. Financial performance
 - 9.2.7.3. Drug benchmarking
 - 9.2.7.4. Strategic initiatives
- 9.2.8. Pfizer
 - 9.2.8.1. Company overview
 - 9.2.8.2. Financial performance
 - 9.2.8.3. Drug benchmarking
 - 9.2.8.4. Strategic initiatives
- 9.2.9. Hospira Inc.
 - 9.2.9.1. Company overview
 - 9.2.9.2. Financial performance
 - 9.2.9.3. Drug benchmarking
 - 9.2.9.4. Strategic initiatives
- 9.2.10. Aspen Pharmacare Holdings Limited
 - 9.2.10.1. Company overview
 - 9.2.10.2. Financial performance
 - 9.2.10.3. Drug benchmarking
 - 9.2.10.4. Strategic initiatives
- 9.2.11. Hikama Pharmaceuticals plc
 - 9.2.11.1. Company overview
 - 9.2.11.2. Financial performance

- 9.2.11.3. Drug benchmarking
- 9.2.11.4. Strategic initiatives
- 9.2.12. Abbott Laboratories
 - 9.2.12.1. Company overview
 - 9.2.12.2. Financial performance
 - 9.2.12.3. Drug benchmarking
 - 9.2.12.4. Strategic initiatives

I would like to order

Product name: U.S. General Anesthesia Drugs Market Size, Share & Trends Analysis Report By Drug (Propofol, Sevoflurane), By Route Of Administration (Intravenous, Inhaled), By End-use (Hospitals, Ambulatory Surgical Centers), By Application, By Country, And Segment Forecasts, 2025 - 2030

Product link: <https://marketpublishers.com/r/UD5167A6A6A3EN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/UD5167A6A6A3EN.html>